-
Effective Treatment for Mental and Substance Use Disorders in 21 Countries. JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-05 Daniel V Vigo,Dan J Stein,Meredith G Harris,Alan E Kazdin,Maria Carmen Viana,Richard Munthali,Lonna Munro,Irving Hwang,Timothy L Kessler,Sophie M Manoukian,Nancy A Sampson,Ronald C Kessler,
Importance Accurate baseline information about the proportion of people with mental disorders who receive effective treatment is required to assess the success of treatment quality improvement initiatives. Objective To examine the proportion of mental and substance use disorders receiving guideline-consistent treatment in multiple countries. Design, Setting, and Participants In this cross-sectional
-
Observational and Genetic Analyses of Traumatic Experiences and Endometriosis JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-05 Dora Koller, Solveig Løkhammer, Oksana Goroshchuk, Veronika Denner, Brendan Stiltner, Marina Mitjans, Jun He, Hugh S. Taylor, Rebecca B. Lawn, Karestan C. Koenen, Renato Polimanti
ImportanceAlthough psychological traumas have been associated with endometriosis, limited information is available regarding the role of trauma type and genetic predisposition.ObjectiveTo examine the relationship between traumatic experiences and endometriosis using observational and genetically informed analyses.Design, Setting, and ParticipantsFor this case-control study, the analyses were performed
-
An Opportunity to Advance Cannabis Science—DEA Rescheduling JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-05 Kevin P. Hill, Anshul V. Puli
This Viewpoint discusses the regulatory and financial barriers to cannabis research, and the potential changes to these barriers if cannabis is reclassified as a Schedule III drug.
-
Changes in Specialty Crisis Services Offered Before and After the Launch of the 988 Suicide and Crisis Lifeline JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-29 Jonathan Cantor, Megan S. Schuler, Rose Kerber, Jonathan Purtle, Ryan K. McBain
ImportanceThe launch of the 988 Suicide and Crisis Lifeline (988) in July 2022 aimed to enhance access to crisis mental health services by replacing the National Suicide Prevention Lifeline with a more memorable number and expanding the Lifeline scope beyond suicide. However, 988’s success relies on the availability of community crisis services.ObjectiveTo examine whether the launch of 988 was associated
-
Psychiatric, Neurological, and Somatic Comorbidities in Intermittent Explosive Disorder JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-22 Yanli Zhang-James, John Paliakkara, Joshua Schaeffer, Joseph Strayhorn, Stephen V. Faraone
ImportanceIntermittent explosive disorder (IED) is an understudied psychiatric condition marked by impulsive aggression and poorly regulated emotional control, often resulting in interpersonal and societal consequences. Better understanding of comorbidities can improve screening, diagnosis, and treatment.ObjectiveTo investigate the prevalence of IED and its associations with psychiatric, neurological
-
Medically Recommended vs Nonmedical Cannabis Use Among US Adults JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-22 Beth Han, Wilson M. Compton, Emily B. Einstein, Nora D. Volkow
This cross-sectional study assesses differences in cannabis use frequency and prevalence of cannabis use disorder between medical-only, medical-nonmedical, and nonmedical-only use among US adults.
-
Social Health and Serious Mental Illness—A Step Forward? JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-22 Jennifer Y. F. Lau, Stefan Priebe, Craig Morgan
This Viewpoint discusses social health, which refers to the quality and quantity of social interactions, relationships, and support networks, as an important independent component of overall health alongside physical and mental health.
-
Bright Light Therapy for Nonseasonal Depressive Disorders-Reply. JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-22 Artur Menegaz de Almeida,Francisco Cezar Aquino Moraes,Francinny Alves Kelly
-
Announcing "Technology and Psychiatry" and Expanding Evidence-Based Comments and Reviews in JAMA Psychiatry. JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-22 Dost Öngür,Roy H Perlis
-
Employment Nondiscrimination Protection and Mental Health Among Sexual Minority Adults JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-15 Michael Liu, Vishal R. Patel, Sahil Sandhu, Rishi K. Wadhera, Alex S. Keuroghlian
ImportanceIn the 2020 Bostock v Clayton County decision, the US Supreme Court extended employment nondiscrimination protection to sexual minority adults. The health impacts of this ruling and similar policies related to sexual orientation–based discrimination are not currently known.ObjectiveTo estimate changes in mental health following the Bostock decision among sexual minority adults in states that
-
Genetic Analysis of Retinal Cell Types in Neuropsychiatric Disorders JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-08 Emanuel Boudriot, Marius Stephan, Finn Rabe, Lukasz Smigielski, Andrea Schmitt, Peter Falkai, Michael J. Ziller, Moritz J. Rossner, Philipp Homan, Sergi Papiol, Florian J. Raabe
ImportanceAs an accessible part of the central nervous system, the retina provides a unique window to study pathophysiological mechanisms of brain disorders in humans. Imaging and electrophysiological studies have revealed retinal alterations across several neuropsychiatric and neurological disorders, but it remains largely unclear which specific cell types and biological mechanisms are involved.ObjectiveTo
-
Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-08 Michelle Matvey, D. Parker Kelley, Ellen R. Bradley, Winston Chiong, Aoife O’Donovan, Josh Woolley
ImportanceThere is unprecedented clinician, industry, and patient interest in the therapeutic development of psychedelic drugs. This is due to a combination of promising clinical trial results, positive media coverage, and the lack of novel pharmacologic treatments for psychiatric disorders in recent decades. However, the field faces a key methodological challenge: masking participants to treatment
-
Requests for Medical Assistance in Dying by Young Dutch People With Psychiatric Disorders JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-02 Lizanne J.S. Schweren, Sanne P.A. Rasing, Monique Kammeraat, Leah A. Middelkoop, Ruthie Werner, Saskia Y.M. Mérelle, Julian M. Garcia, Daan H.M. Creemers, Sisco M.P. van Veen
ImportanceIn the Netherlands, a growing group of young people request medical assistance in dying based on psychiatric suffering (MAID-PS). Little is known about this group, their characteristics, and outcomes.ObjectiveTo assess the proportion of requests for and deaths by MAID-PS among young patients, outcomes of their application and assessment procedures, and characteristics of those patients who
-
What the Experiences of Young Persons Can Teach Us About Medical Aid in Dying for Psychiatric Illness. JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-02 Brent Kious
-
The Promise and Perils of Using Peers and Other Paraprofessionals as Mental Health Service Professionals JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-02 Patricia A. Areán, Stephen O’Connor, Joel Sherrill
This Viewpoint discusses better integration of peer support specialists and other paraprofessionals into clinical and community practice settings to help address the behavioral health workforce shortage.
-
Social Determinants of Health and Suicide-Related Outcomes JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-02 Peter Jongho Na, Jeonghyun Shin, Ha Rim Kwak, Jaewon Lee, Dylan J. Jester, Piumee Bandara, Jim Yong Kim, Christine Y. Moutier, Robert H. Pietrzak, Maria A. Oquendo, Dilip V. Jeste
ImportancePreventing suicide is one of the top priorities in public health policy. Identifying key social determinants of health (SDOH) in suicide risk is critical for informing clinical practices, future research, and policy solutions to prevent suicide.ObjectiveTo examine the associations of SDOH with suicide-related outcomes.Data SourcesStudies published before July 2023 were searched through PubMed
-
Left Ventrolateral Prefrontal Cortical Activity During Reward Expectancy and Mania Risk JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-02 Manan Arora, Henry Chase, Michele A. Bertocci, Alexander S. Skeba, Kristen Eckstrand, Genna Bebko, Haris A. Aslam, Robert Raeder, Simona Graur, Osasumwen Benjamin, Yiming Wang, Richelle S. Stiffler, Mary L. Phillips
ImportanceMania/hypomania is the pathognomonic feature of bipolar disorder (BD). As BD is often misdiagnosed as major depressive disorder (MDD), replicable neural markers of mania/hypomania risk are needed for earlier BD diagnosis and pathophysiological treatment development.ObjectiveTo replicate the previously reported positive association between left ventrolateral prefrontal cortex (vlPFC) activity
-
Association of State Cannabis Legalization With Cannabis Use Disorder and Cannabis Poisoning JAMA Psychiatry (IF 22.5) Pub Date : 2024-12-23 Jayani Jayawardhana, Jialin Hou, Patricia Freeman, Jeffery C. Talbert
ImportanceWhether state implementation of medical and recreational cannabis laws is associated with increased cannabis use disorder (CUD) and/or cannabis poisoning among adults is not evident.ObjectiveTo examine state-level medical and recreational cannabis laws’ associations with CUD and cannabis poisoning, overall and by sex and age subgroups.Design, Setting, and ParticipantsIn this longitudinal
-
Does Vaccination Really Mitigate Psychiatric Implications of COVID-19?-Reply. JAMA Psychiatry (IF 22.5) Pub Date : 2024-12-18 Venexia M Walker,Praveetha Patalay,Jonathan A C Sterne
-
Does Vaccination Really Mitigate Psychiatric Implications of COVID-19? JAMA Psychiatry (IF 22.5) Pub Date : 2024-12-18 Yaakov Ophir,Yaffa Shir-Raz
-
Youth Generalized Anxiety and Brain Activation States During Socioemotional Processing JAMA Psychiatry (IF 22.5) Pub Date : 2024-12-18 M. Catalina Camacho, Rebecca F. Schwarzlose, Michael T. Perino, Alyssa K. Labonte, Sanju Koirala, Deanna M. Barch, Chad M. Sylvester
ImportanceThe brain enters distinct activation states to support differential cognitive and emotional processes, but little is known about how brain activation states differ in youths with clinical anxiety.ObjectiveTo characterize brain activation states during socioemotional processing (movie stimuli) and assess associations between state characteristics and movie features and anxiety symptoms.Design
-
Brexpiprazole and Sertraline Combination Treatment in Posttraumatic Stress Disorder JAMA Psychiatry (IF 22.5) Pub Date : 2024-12-18 Lori L. Davis, Saloni Behl, Daniel Lee, Hui Zeng, Taisa Skubiak, Shelley Weaver, Nanco Hefting, Klaus Groes Larsen, Mary Hobart
ImportanceNew pharmacotherapy options are needed for posttraumatic stress disorder (PTSD).ObjectiveTo investigate the efficacy, safety, and tolerability of brexpiprazole and sertraline combination treatment (brexpiprazole + sertraline) compared with sertraline + placebo for PTSD.Design, Setting, and ParticipantsThis was a parallel-design, double-blind, randomized clinical trial conducted from October
-
Neurofeedback for Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-01 Samuel J Westwood,Pascal-M Aggensteiner,Anna Kaiser,Peter Nagy,Federica Donno,Dóra Merkl,Carla Balia,Allison Goujon,Elisa Bousquet,Agata Maria Capodiferro,Laura Derks,Diane Purper-Ouakil,Sara Carucci,Martin Holtmann,Daniel Brandeis,Samuele Cortese,Edmund J S Sonuga-Barke,
Importance Neurofeedback has been proposed for the treatment of attention-deficit/hyperactivity disorder (ADHD) but the efficacy of this intervention remains unclear. Objective To conduct a meta-analysis of randomized clinical trials (RCTs) using probably blinded (ie, rated by individuals probably or certainly unaware of treatment allocation) or neuropsychological outcomes to test the efficacy of neurofeedback
-
Private Equity Ownership of US Opioid Treatment Programs. JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-01 David T Zhu,Zirui Song,Sneha Kannan,Christopher L Cai,Simar S Bajaj,Suhas Gondi
-
Linking Genome-Wide Association Studies to Pharmacological Treatments for Psychiatric Disorders JAMA Psychiatry (IF 22.5) Pub Date : 2024-12-11 Aurina Arnatkeviciute, Alex Fornito, Janette Tong, Ken Pang, Ben D. Fulcher, Mark A. Bellgrove
ImportanceLarge-scale genome-wide association studies (GWAS) should ideally inform the development of pharmacological treatments, but whether GWAS-identified mechanisms of disease liability correspond to the pathophysiological processes targeted by current pharmacological treatments is unclear.ObjectiveTo investigate whether functional information from a range of open bioinformatics datasets can elucidate
-
Treatment Expectancies and Psilocybin vs Escitalopram for Depression JAMA Psychiatry (IF 22.5) Pub Date : 2024-12-10 Ethan G. Dutcher, Andrew D. Krystal
This randomized controlled trial secondary analysis examines the association between treatment expectancies and the relative efficacy of psilocybin compared with escitalopram for major depressive disorder.
-
Psychological Interventions for Pediatric Posttraumatic Stress Disorder JAMA Psychiatry (IF 22.5) Pub Date : 2024-12-04 Thole H. Hoppen, Lena Wessarges, Marvin Jehn, Julian Mutz, Ahlke Kip, Pascal Schlechter, Richard Meiser-Stedman, Nexhmedin Morina
ImportancePediatric posttraumatic stress disorder (PTSD) is a common and debilitating mental disorder, yet a comprehensive network meta-analysis examining psychological interventions is lacking.ObjectiveTo synthesize all available evidence on psychological interventions for pediatric PTSD in a comprehensive systematic review and network meta-analysis.Data SourcesPsycINFO, MEDLINE, Web of Science, and
-
Trends in Outpatient Psychotherapy Among Adults in the US JAMA Psychiatry (IF 22.5) Pub Date : 2024-12-04 Mark Olfson, Chandler McClellan, Samuel H. Zuvekas, Melanie Wall, Carlos Blanco
ImportanceWhile access to psychotherapy has recently increased in the US, concern exists that recent gains may be unevenly distributed despite teletherapy expansion.ObjectiveTo characterize recent trends and patterns in outpatient psychotherapy by US adults.Design, Setting, and ParticipantsThis is a repeated cross-sectional study of psychotherapy use among adults (ages ≥18 years) in the 2018 to 2021
-
Capturing the Full Range of Buprenorphine Treatment Response JAMA Psychiatry (IF 22.5) Pub Date : 2024-12-04 Allen J. Bailey, Victoria R. Votaw, Roger D. Weiss, R. Kathryn McHugh
ImportanceReliance on abstinence-based treatment success rules may fail to capture the full continuum of treatment response to buprenorphine plus medical counseling (BUP+MC) for opioid use disorder (OUD).ObjectiveTo describe patterns of reduction in illicit opioid use of patients both labeled as a success and nonsuccess based on an abstinent-based treatment outcome rule.Design, Setting, and ParticipantsThis
-
Characteristics of Adults Treated at Mental Health Treatment Centers in the US, 2022 JAMA Psychiatry (IF 22.5) Pub Date : 2024-11-27 Susan H. Busch, Jason Hockenberry, Helen Newton
This cross-sectional study examines demographic characteristics of adults treated at outpatient mental health treatment centers using data from the 2022 US National Survey of Drug Use and Health.
-
Mental Health Disorder Trends in Denmark According to Age, Calendar Period, and Birth Cohort JAMA Psychiatry (IF 22.5) Pub Date : 2024-11-27 Natalie C. Momen, Christoffer Beck, Mette Lise Lousdal, Esben Agerbo, John J. McGrath, Carsten B. Pedersen, Merete Nordentoft, Oleguer Plana-Ripoll
ImportanceResearch suggests an increase in mental disorder incidence in recent years, but this trend remains unexplained, and there is a lack of large studies based on a representative sample that investigate mental disorders over the full spectrum.ObjectiveTo explore sex- and age-specific incidence of any mental disorder and 19 specific disorders according to birth cohort and calendar period.Design
-
A Framework for Suicide Risk Screening After Overdose JAMA Psychiatry (IF 22.5) Pub Date : 2024-11-27 Matthew Robert Dernbach, Randi N. Smith, Joseph E. Carpenter
This Viewpoint proposes applying a systematic curriculum for early management of traumatically injured patients as a framework for suicide risk screening after overdose.
-
War Exposure and DNA Methylation in Syrian Refugee Children and Adolescents JAMA Psychiatry (IF 22.5) Pub Date : 2024-11-20 Demelza Smeeth, Simone Ecker, Olga Chervova, Fiona McEwen, Elie Karam, Stephan Beck, Michael Pluess
ImportanceExposure to war is associated with poor mental health outcomes. Adverse and traumatic experiences can lead to long-lasting DNA methylation changes, potentially mediating the link between adversity and mental health. To date, limited studies have investigated the impact of war on DNA methylation in children or adolescents, hampering our understanding of the biological impact of war exposure
-
Ending Unequal Treatment for People With Behavioral Health Conditions JAMA Psychiatry (IF 22.5) Pub Date : 2024-11-20 Ruth S. Shim, Margarita Alegría
This Viewpoint discusses the “Ending Unequal Treatment: Strategies to Achieve Equitable Health Care and Optimal Health for All” report, which emphasizes that health inequities lead to poor mental health for all people, not only minoritized populations, and a diverse workforce is needed to achieve mental health equity.
-
How the Paternal Brain Is Wired by Pregnancy. JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-01 Hugo Bottemanne,Lucie Joly
-
Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder JAMA Psychiatry (IF 22.5) Pub Date : 2024-11-13 Markku Lähteenvuo, Jari Tiihonen, Anssi Solismaa, Antti Tanskanen, Ellenor Mittendorfer-Rutz, Heidi Taipale
ImportancePreliminary studies suggest that glucagon-like peptide-1 receptor (GLP-1) agonists, used to treat type 2 diabetes and obesity, may decrease alcohol consumption.ObjectiveTo test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.Design, Setting, and ParticipantsThis cohort
-
Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder JAMA Psychiatry (IF 22.5) Pub Date : 2024-11-13 Daniel T. Myran, Michael Pugliese, Jennifer Xiao, Tyler S. Kaster, M. Ishrat Husain, Kelly K. Anderson, Nicholas Fabiano, Stanley Wong, Jess G. Fiedorowicz, Colleen Webber, Peter Tanuseputro, Marco Solmi
ImportanceInterest in and use of hallucinogens has been increasing rapidly. While a frequently raised concern is that hallucinogens may be associated with an increased risk of psychosis, there are limited data on this association.ObjectivesTo examine whether individuals with an emergency department (ED) visit involving hallucinogen use have an increased risk of developing a schizophrenia spectrum disorder
-
Grief-Specific Cognitive Behavioral Therapy vs Present-Centered Therapy JAMA Psychiatry (IF 22.5) Pub Date : 2024-11-13 Rita Rosner, Jörn Rau, Anette Kersting, Winfried Rief, Regina Steil, Anna-Maria Rummel, Anna Vogel, Hannah Comtesse
ImportanceProlonged grief disorder (PGD) is included as a new diagnosis in international classification systems. Treatments following a cognitive behavioral model are most effective, but comparisons with active control treatments are scarce.ObjectiveTo examine whether integrative cognitive behavioral therapy for prolonged grief (PG-CBT) is superior to present-centered therapy (PCT).Design, Setting
-
Synaptic Density in Early Stages of Psychosis and Clinical High Risk JAMA Psychiatry (IF 22.5) Pub Date : 2024-11-13 M. Belen Blasco, Kankana Nisha Aji, Christian Ramos-Jiménez, Ilana Ruth Leppert, Christine Lucas Tardif, Johan Cohen, Pablo M. Rusjan, Romina Mizrahi
ImportanceSynaptic dysfunction is involved in schizophrenia pathophysiology. However, whether in vivo synaptic density is reduced in early stages of psychosis, including its high-risk states, remains unclear.ObjectiveTo investigate whether synaptic density (synaptic vesicle glycoprotein 2A [SV2A] binding potential) is reduced in first-episode psychosis (FEP) and in clinical high risk (CHR) and investigate
-
Neuroinflammation, Stress-Related Suicidal Ideation, and Negative Mood in Depression JAMA Psychiatry (IF 22.5) Pub Date : 2024-11-06 Sarah Herzog, Elizabeth A. Bartlett, Francesca Zanderigo, Hanga C. Galfalvy, Ainsley Burke, Akiva Mintz, Mike Schmidt, Eric Hauser, Yung-yu Huang, Nadine Melhem, M. Elizabeth Sublette, Jeffrey M. Miller, J. John Mann
ImportanceBrain translocator protein 18k Da (TSPO) binding, a putative marker of neuroinflammatory processes (eg, gliosis), is associated with stress and elevated in depressed and suicidal populations. However, it is unclear whether neuroinflammation moderates the impact of daily life stress on suicidal ideation and negative affect, thereby increasing risk for suicidal behavior.ObjectiveTo examine
-
Psychosis Spectrum Symptoms Before and After Adolescent Cannabis Use Initiation JAMA Psychiatry (IF 22.5) Pub Date : 2024-11-06 K. Juston Osborne, Deanna M. Barch, Joshua J. Jackson, Nicole R. Karcher
ImportanceAdolescent cannabis use has been consistently posited to contribute to the onset and progression of psychosis. However, alternative causal models may account for observed associations between cannabis use and psychosis risk, including shared vulnerability for both cannabis use and psychosis or efforts to self-medicate distress from psychosis spectrum symptomology.ObjectiveTo test 3 hypotheses
-
Racial and Ethnic Disparities in Fentanyl and Polysubstance Overdose Deaths JAMA Psychiatry (IF 22.5) Pub Date : 2024-11-06 David T. Zhu
This cross-sectional study describes US overdose death patterns for fentanyl and fentanyl combined with opioids, heroin, cocaine, methamphetamine, or benzodiazepines by race and ethnicity from 2010 to 2022.
-
TikTok Challenges—Unintentional Injuries vs Suicide Attempts JAMA Psychiatry (IF 22.5) Pub Date : 2024-11-06 Onomeasike Ataga, Valerie K. Arnold
This Viewpoint discusses injuries among US children that are attributable to TikTok challenges, addresses the challenge of distinguishing between unintentional injuries and suicide attempts, and explores potential methods of prevention, treatment, and clinical disposition for such injuries.
-
Slowing Cognitive Decline in Major Depressive Disorder and Mild Cognitive Impairment: A Randomized Clinical Trial. JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-01 Tarek K Rajji,Christopher R Bowie,Nathan Herrmann,Bruce G Pollock,Krista L Lanctôt,Sanjeev Kumar,Alastair J Flint,Linda Mah,Corinne E Fischer,Meryl A Butters,Marom Bikson,James L Kennedy,Daniel M Blumberger,Zafiris J Daskalakis,Damien Gallagher,Mark J Rapoport,Nicolaas P L G Paul Verhoeff,Angela C Golas,Ariel Graff-Guerrero,Erica Vieira,Aristotle N Voineskos,Heather Brooks,Ashley Melichercik,Kevin
Importance Older adults with major depressive disorder (MDD) or mild cognitive impairment (MCI) are at high risk for cognitive decline. Objective To assess the efficacy of cognitive remediation (CR) plus transcranial direct current stimulation (tDCS) targeting the prefrontal cortex in slowing cognitive decline, acutely improving cognition, and reducing progression to MCI or dementia in older adults
-
Depression Diagnosis, Treatment, and Remission Among Adults in India JAMA Psychiatry (IF 22.5) Pub Date : 2024-10-30 Felix Teufel, Aastha Aggarwal, Lydia Chwastiak, Vikram Patel, Mohammed K. Ali
ImportanceDepression is a leading contributor to mental health burdens globally and in India, the world’s most populous country. National-level evidence on health coverage for adults with depression in India is lacking.ObjectiveTo estimate proportions of middle-aged and older adults with depression in India who used health care services, were diagnosed with depression, received treatment, and were
-
Sexual Trauma, Polygenic Scores, and Mental Health Diagnoses and Outcomes JAMA Psychiatry (IF 22.5) Pub Date : 2024-10-30 Allison M. Lake, Yu Zhou, Bo Wang, Ky’Era V. Actkins, Yingzhe Zhang, John P. Shelley, Anindita Rajamani, Michael Steigman, Chris J. Kennedy, Jordan W. Smoller, Karmel W. Choi, Nikhil K. Khankari, Lea K. Davis
ImportanceLeveraging real-world clinical biobanks to investigate the associations between genetic and environmental risk factors for mental illness may help direct clinical screening efforts and evaluate the portability of polygenic scores across environmental contexts.ObjectiveTo examine the associations between sexual trauma, polygenic liability to mental health outcomes, and clinical diagnoses of
-
Posttraumatic Stress Disorder, Obesity, and Accelerated Epigenetic Aging Among US Military Veterans JAMA Psychiatry (IF 22.5) Pub Date : 2024-10-30 Ian C. Fischer, Peter J. Na, Sheila T. Nagamatsu, Dilip V. Jeste, Brenda Cabrera-Mendoza, Janitza L. Montalvo-Ortiz, John H. Krystal, Renato Polimanti, Joel Gelernter, Robert H. Pietrzak
This cross-sectional study uses data from 1135 male, European-American US military veterans to assess whether risk and protective factors influenced associations between posttraumatic stress disorder and epigenetic age.
-
Antipsychotic Monotherapy vs Polytherapy for Pneumonia Risk. JAMA Psychiatry (IF 22.5) Pub Date : 2024-12-01 Yuki Kikuchi,Hiroshi Komatsu,Hiroaki Tomita
-
Antipsychotic Monotherapy vs Polytherapy for Pneumonia Risk-Reply. JAMA Psychiatry (IF 22.5) Pub Date : 2024-12-01 Jurjen J Luykx,Jari Tiihonen,Heidi Taipale
-
Traumatic and Adverse Childhood Experiences and Developmental Differences in Psychiatric Risk JAMA Psychiatry (IF 22.5) Pub Date : 2024-10-23 Justin D. Russell, Sara A. Heyn, Matthew Peverill, Samantha DiMaio, Ryan J. Herringa
ImportanceWhile adverse childhood experiences (ACEs) are known to impart significant risk for negative mental health and cognitive outcomes in youth, translation of ACE scores into clinical intervention is limited by poor specificity in predicting negative outcomes. This work expands on the ACE framework using a data-driven approach to identify 8 different forms of traumatic and adverse childhood experiences
-
Diagnosing and Treating ADHD in Adults JAMA Psychiatry (IF 22.5) Pub Date : 2024-10-23 Carlos Blanco, Craig B. H. Surman
This Viewpoint advocates for proactively addressing concerns related to the diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD) in US adults to balance individual benefits with population-level risk.
-
Development of Sensory Regions vs the Rest of the Cortex in Autism. JAMA Psychiatry (IF 22.5) Pub Date : 2024-12-01 Jessica Girault
-
Patterns of Brain Maturation in Autism and Their Molecular Associations. JAMA Psychiatry (IF 22.5) Pub Date : 2024-12-01 Charlotte M Pretzsch,Martina Arenella,Jason P Lerch,Michael V Lombardo,Christian Beckmann,Tim Schaefer,Johanna Leyhausen,Caroline Gurr,Anke Bletsch,Lisa M Berg,Hanna Seelemeyer,Dorothea L Floris,Bethany Oakley,Eva Loth,Thomas Bourgeron,Tony Charman,Jan Buitelaar,Grainne McAlonan,Declan Murphy,Christine Ecker,
Importance In the neurotypical brain, regions develop in coordinated patterns, providing a fundamental scaffold for brain function and behavior. Whether altered patterns contribute to clinical profiles in neurodevelopmental conditions, including autism, remains unclear. Objectives To examine if, in autism, brain regions develop differently in relation to each other and how these differences are associated
-
Toward Equitable Interventions in Public Mental Health JAMA Psychiatry (IF 22.5) Pub Date : 2024-10-16 Ulrich Reininghaus, Annika S. Reinhold, Stefan Priebe, Christian Rauschenberg, Leonie Fleck, Anita Schick, Frederike Schirmbeck, Inez Myin-Germeys, Craig Morgan, Jessica A. Hartmann
ImportanceThe field of public mental health is evolving to tackle the profound impact of global challenges such as climate change, migration, and health crises. These issues accentuate health and social inequities, necessitating a focus on how to achieve interventions that are equitable and enhance mental health across all societal strata.ObservationsPopulation-based interventions can inadvertently
-
Antipsychotic Drugs and Cognitive Function JAMA Psychiatry (IF 22.5) Pub Date : 2024-10-16 Lena Feber, Natalie L. Peter, Virginia Chiocchia, Johannes Schneider-Thoma, Spyridon Siafis, Irene Bighelli, Wulf-Peter Hansen, Xiao Lin, Daniel Prates-Baldez, Georgia Salanti, Richard S. E. Keefe, Rolf R. Engel, Stefan Leucht
ImportanceCognitive deficits are a substantial part of the symptoms of schizophrenia spectrum disorders (SSDs) and contribute heavily to the burden of disease. Antipsychotic drugs are not cognitive enhancers, but due to their different receptor-binding profiles, they could differ in their effects on cognition. No previous network meta-analysis compared antipsychotics to placebo, which is important
-
Addressing the Escalating Problems That Patients Encounter When Filling Buprenorphine Prescriptions JAMA Psychiatry (IF 22.5) Pub Date : 2024-10-16 Erin L. Winstanley, Angela Gray, Douglas Thornton
This Viewpoint describes both the current barriers patients face when filling their prescriptions for buprenorphine at pharmacies and a list of proposed fixes requiring changes at the federal, state, insurance, and clinician level.
-
An Architecture for Transformation in Child Mental Health JAMA Psychiatry (IF 22.5) Pub Date : 2024-10-09 John N. Constantino, Laura J. Dilly
This Viewpoint describes efforts to provide timely, comprehensive, and high-quality mental health care to a large population-representative subset of children within a single health system and demonstrate its potential impact and true cost.
-
Deconstructing Cognitive Impairment in Psychosis With a Machine Learning Approach JAMA Psychiatry (IF 22.5) Pub Date : 2024-10-09 Robert A. McCutcheon, Richard S. E. Keefe, Philip M. McGuire, Andre Marquand
ImportanceCognitive functioning is associated with various factors, such as age, sex, education, and childhood adversity, and is impaired in people with psychosis. In addition to specific effects of the disorder, cognitive impairments may reflect a greater exposure to general risk factors for poor cognition.ObjectiveTo determine the extent that impairments in cognition in psychosis reflect risk factor
-
Informant Effect on Placebo Response in Mental Disorders-Reply. JAMA Psychiatry (IF 22.5) Pub Date : 2024-11-01 Tom Bschor,Christopher Baethge
-
Informant Effect on Placebo Response in Mental Disorders. JAMA Psychiatry (IF 22.5) Pub Date : 2024-11-01 Toshi A Furukawa,Pim Cuijpers